Contaminant Discovered In Chinese-Produced Heparin API
This article was originally published in PharmAsia News
Executive Summary
U.S FDA has discovered "significant quantities" of a heparin-like contaminant in tested samples of heparin API manufactured by Baxter-supplier Scientific Protein Laboratories' Changzhou plant
You may also be interested in...
U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation
The House Energy & Commerce Subcommittee on Oversight and Investigations simultaneously lauded and criticized U.S. FDA's handling of the heparin contaminant safety issue, which FDA now says was most likely the result of intentional actions
U.S. FDA’s Poor Performance ‘Invites Catastrophe’ – U.S. Congressional Committee On Heparin Investigation
The House Energy & Commerce Subcommittee on Oversight and Investigations simultaneously lauded and criticized U.S. FDA's handling of the heparin contaminant safety issue, which FDA now says was most likely the result of intentional actions
Chinese Contaminant Was Inexpensive Heparin Mimic – U.S. FDA
U.S. FDA has identified the contaminant found in heparin linked to hundreds of adverse events as synthetically altered over-sulfated chondroitin sulfate, the agency announced during a March 19 conference call